The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
Author:
Funder
Institut National de la Santé et de la Recherche Médicale
Centre National de la Recherche Scientifique
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference123 articles.
1. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet.,2016
2. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial;Calabro;Lancet Oncol.,2013
3. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial;Maio;Lancet Oncol.,2017
4. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial;Scherpereel;Lancet Oncol.,2019
5. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity;Adusumilli;Sci Transl Med.,2014
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies;Pharmaceuticals;2024-08-09
2. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement;Expert Opinion on Therapeutic Targets;2023-11-02
3. The cytological features of effusions with mesothelioma in situ: A report of 9 cases;Diagnostic Cytopathology;2023-03-21
4. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics;Frontiers in Immunology;2023-01-04
5. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4 /6 inhibition;Molecular Oncology;2022-12-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3